Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study
Guiling Li,1,* Mingxia Cheng,1,* Kai Hong,2,* Yao Jiang1 1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 2Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazh...
Main Authors: | Li G, Cheng M, Hong K, Jiang Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-03-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-efficacy-and-safety-of-immunotherapy-retreatment-in-metastati-peer-reviewed-fulltext-article-OTT |
Similar Items
-
Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives
by: Zhichao Tian, et al.
Published: (2024-02-01) -
Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: a systematic review and single-arm meta-analysis
by: Min Chen, et al.
Published: (2024-01-01) -
Efficacy and safety of nab-paclitaxel chemotherapy for patients with gastric carcinoma: A systematic review and single arm meta-analysis
by: Alyaa Khaled Madeeh, et al.
Published: (2024-01-01) -
A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
by: Qingyuan Zhang, et al.
Published: (2022-10-01) -
Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
by: Md Sazzad Hassan, et al.
Published: (2023-07-01)